Cancer Treat Rev 2011 Dec;37 (8): 633-42. [IF:6.811]
Liposome based delivery systems in pancreatic cancer treatment: from bench to bedside.
Yang F , Jin C , Jiang Y , Li J , Di Y , Ni Q , Fu D .
Pancreatic Disease Institute, Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China. yffudan98@126.com
上海复旦大学，复旦大学附属华山医院胰腺外科，胰腺疾病研究所
Abstract
Despite rapid advances in cancer diagnosis and treatment, pancreatic cancer remains one of the most difficult human malignancies to be treated, with a mortality rate nearly equal to its incidence. Although gemcitabine has been established as the standard first-line treatment for advanced pancreatic cancer, gemcitabine-based combination chemotherapy showed either marginal or no improvement in survival. Developments in liposomal delivery systems have facilitated the targeting of specific agents for cancer treatment. Such systems could be developed as platforms for future multi-functional theranostic nanodevices tailor-made for the combined detection of early cancer and functional drug delivery. We systemically review liposome based drug-delivery systems, which can provide improved pharmacokinetics, reduced side effects and potentially increased tumor uptake, for pancreatic cancer therapy. Novel liposomal formulations allowing for higher tumor targeting efficiencies and used in current clinical trials to treat this challenging disease are emphasized.
摘要
尽管肿瘤诊断和治疗已取得了快速的发展，但由于病死率与发病率几乎相等，所以胰腺癌仍是最难治疗的人类恶性肿瘤之一。虽然吉西他滨已经被确定作为治疗晚期胰腺癌的一线标准用药，但是以吉西他滨为基础的联合化疗方案对患者生存率的提高只起到了相当微弱的作用或者根本未能显效。脂质体药物投递系统的发展已经使特定药物对肿瘤治疗部位的靶向变得容易。该系统可能会被发展成未来可定制的多功能诊治一体化纳米器件平台，此类平台结合了肿瘤早期检测和药物投递功能于一身。我们系统性地回顾了基于脂质体的药物投递系统研究历程，认为将脂质体药物投递系统应用于胰腺癌治疗中可以改善抗肿瘤药物药动学过程，降低副作用并且显著增加瘤细胞对的摄取。新型脂质体制剂受到了重视，因其具有更强的肿瘤靶向效力，并且目前已被用于临床试验去治疗这一极具挑战性的疾病。
尚有不足之处烦请站友指正。
